BunyaVax provides technology to develop a human Rift Valley Fever vaccine in a $12.5 million project

BunyaVax provides technology to develop a human Rift Valley Fever vaccine in a $12.5 million project financed by CEPI BunyaVax is technology provider in a consortium led by Wageningen Bioveterinary Research and financed by CEPI to develop a human vaccine against Rift Valley Fever. With support from the European Union’s (EU’s) Horizon 2020 programme, CEPI will provide up to US$12.5 million for vaccine manufacturing, preclinical research, and a phase 1 study to assess the safety, tolerability, and immunogenicity of a single-dose vaccine candidate (RVFV-4s) against Rift Valley fever virus for use in humans. To produce this vaccine candidate, researchers at WBVR have altered the genome of the Ri

© 2018 by BunyaVax.